BiotechTube
Polygon Therapeutics

Polygon Therapeutics

Paris, France· Est.
polygon.care
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Polygon Therapeutics is a Paris-based, preclinical-stage biotech targeting the significant unmet medical need in cardiovascular diseases through immunotherapies. Its lead asset, PLG-101, is a human anti-CD8 monoclonal antibody shown in nonclinical models to reduce infarct size by 60% and improve heart function by 25% following a heart attack. The company is built on strong foundational science from its co-founders, including a leading clinician-scientist, and is positioned at the forefront of the nascent but promising cardio-immunology field. Its strategy involves advancing PLG-101 towards clinical trials while building out a broader discovery platform.

CardiovascularImmunology

Technology Platform

CARDINAL: A cardio-immunology discovery and development platform focused on exploring and modulating immune pathways, particularly involving CD8+ T cells, that drive cardiovascular disease pathology. It integrates target discovery, antibody engineering, and biomarker development.

Funding History

1
SeedUndisclosed

Opportunities

The global burden of cardiovascular disease represents a massive, underserved market.
Success with PLG-101 could establish a new treatment paradigm (cardio-immunology) and create a blockbuster product.
The company's platform could generate a pipeline of immunomodulatory drugs for various cardiac conditions.

Risk Factors

High risk of failure in translating preclinical results to human efficacy and safety.
As a first-in-class modality, it faces significant regulatory and clinical development challenges.
The emerging field may attract well-capitalized competitors.

Competitive Landscape

The cardio-immunology field is nascent, with few direct competitors. Polygon appears to be a pioneer with a specific anti-CD8 antibody for acute MI. Competition may come from other biotechs exploring immune targets in CVD or from large pharma entering the space later. Traditional cardiology drug developers represent indirect competition.

More companies in Biologics / Biosimilars →More companies in France →